Literature DB >> 499305

Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.

C T Ueda, B S Dzindzio.   

Abstract

The pharmacokinetics of dihydroquinidine were studied in 8 patients with congestive heart failure following a 22 min intravenous infusion of a quinidine preparation that contained 5.9% dihydroquinidine as an impurity. Using a thin layer chromatography-fluorometric assay procedure for dihydroquinidine, the post-infusion plasma dihydroquinidine concentrations declined biexponentially. The half-life of the fast and slow dispositional processes was 4.42 +/- 1.81 min and 6.52 +/- 2.40 h, respectively. The central compartment volume for dihydroquinidine in these patients was 0.44 +/- 0.11 l/kg with an overall apparent volume of distribution of 1.14 +/- 0.38 l/kg. The computed values of total body plasma clearance of dihydroquinidine ranged from 1.29 to 2.69 ml/min/kg with a mean value of 1.94 +/- 0.60 ml/min/kg. In these patients, approximately 16% of the administered dihydroquinidine dose was excreted intact into the urine in 48 h. The estimated value of renal clearance was 0.314 +/- 0.129 ml/min/kg. When compared to control cardiac patients, the data showed that the apparent volume of distribution for dihydroquinidine is smaller in patients with congestive heart failure and as a result of this diminished volume, the clearance rate of dihydroquinidine was slower. The net effect of these differences was the production of higher plasma concentrations of dihydroquinidine in the heart failure group.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499305     DOI: 10.1007/bf00563115

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Ventricular tachycardia following the administration of quinidine.

Authors:  D G WETHERBEE; D HOLZMAN; M G BROWN
Journal:  Am Heart J       Date:  1952-01       Impact factor: 4.749

Review 2.  Drug disposition and liver disease.

Authors:  G R Wilkinson; S Schenker
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

3.  Disposition kinetics of dihydroquinidine following quinidine administration.

Authors:  C T Ueda; B J Williamson; B S Dzindzio
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-06

4.  Examination of quinidine and quinine and their pharmaceutical preparations.

Authors:  E Smith; S Barkan; B Ross; M Maienthal; J Levine
Journal:  J Pharm Sci       Date:  1973-07       Impact factor: 3.534

5.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

6.  Quinidine kinetics in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

Review 7.  Renal failure, drug pharmacokinetics and drug action.

Authors:  J Fabre; L Balant
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 8.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Comparison of effects of quinidine and dihydroquinidine on canine heart.

Authors:  T Balazs; E Herman; J Atkinson
Journal:  J Pharm Sci       Date:  1978-10       Impact factor: 3.534

10.  Drug administration in renal failure.

Authors:  J S Cheigh
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

View more
  1 in total

1.  Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.

Authors:  P Jaillon; J M Poirier; B Lecocq; C Jarreau; M Pays; M O Richard; G Cheymol
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.